Table 1 |
|||||
|
Clinically significant upper and lower GI events: primary analysis |
|||||
|
Celecoxib |
nsNSAID |
||||
|
|
|||||
|
N |
Patients With Event n (%) |
N |
Patients With Event n (%) |
||
|
|
|||||
|
All patients |
4035 |
54 (1.3) |
4032 |
98 (2.4) |
|
|
|
|||||
|
H pylori status |
Positive |
1401 |
25 (1.8) |
1386 |
34 (2.5) |
|
|
|||||
|
Negative |
2634 |
29 (1.1) |
2646 |
64 (2.4) |
|
|
|
|||||
|
OR (95% CI); P value |
1.82 (1.31-2.55); p = 0.0003 |
||||
|
|
|||||
|
Cryer et al. Arthritis Research & Therapy 2012 14(Suppl 1):P63 doi:10.1186/ar3664 |
|||||